Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.

The Ag specificity of the CTL response against CMV is directed almost entirely to a single CMV tegument protein, the phosphoprotein pp65. We report the identification of three peptides derived from the protein pp65 that displayed a high or intermediate binding to HLA-A*0201 molecules, which were also able to induce an in vitro CTL response in peripheral blood lymphocytes from CMV seropositive individuals. The peptide-specific CTLs generated were capable of recognizing the naturally processed pp65 either presented by CMV-infected cells or by cells infected with an adenovirus construct expressing pp65 in an HLA-A*0201-restricted manner. Thus, we were able to demonstrate responses to subdominant CTL epitopes in CMV-pp65 that were not detected in polyclonal cultures obtained by conventional stimulations. We also found that the amino acid sequences of the three peptides identified as HLA-A*0201-restricted CTL epitopes were conserved among different wild-type strains of CMV obtained from renal transplant patients, an AIDS patient, and a congenitally infected infant, as well as three laboratory strains of the virus (AD169, Towne and Davis). These observations suggest that these pp65 CTL peptide epitopes could potentially be used as synthetic peptide vaccines or for other therapeutic strategies aimed at HLA-A*0201-positive individuals, who represent approximately 40% of the European Caucasoid population. However, strain variation must be taken in consideration when the search for CTL epitopes is extended to other HLA class I alleles, because these mutations may span potential CTL epitopes for other HLA molecules, as it is described in this study.

[1]  M. Weekes,et al.  The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo , 1999, Journal of Virology.

[2]  P. Parham,et al.  The influence of exogenous peptide on β2–microglobulin exchange in the HLA complex: analysis in real-time , 1998, Immunogenetics.

[3]  L. Hsiao,et al.  A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. , 1997, Journal of immunological methods.

[4]  J. York,et al.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.

[5]  H. Rammensee,et al.  Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. , 1997, The Journal of general virology.

[6]  P. A. Peterson,et al.  The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. , 1997, Immunity.

[7]  X. Jin,et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.

[8]  J. Grundy,et al.  Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. , 1996, Transplantation.

[9]  U. Koszinowski,et al.  Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. , 1996, The Journal of general virology.

[10]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[11]  S. H. van der Burg,et al.  An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. , 1995, Human immunology.

[12]  L. Sun,et al.  Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains , 1995, Journal of virology.

[13]  P. Klenerman,et al.  The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus , 1995, European journal of immunology.

[14]  R. Zinkernagel,et al.  Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus , 1995, Journal of virology.

[15]  D. Speiser,et al.  Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. , 1994, Human immunology.

[16]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[17]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[18]  S. Riddell,et al.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.

[19]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[21]  S. Riddell,et al.  Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus , 1993, Journal of virology.

[22]  M. Masucci,et al.  HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. , 1993, Science.

[23]  G. Wilkinson,et al.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. , 1992, Nucleic acids research.

[24]  M. Bednarek,et al.  The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. , 1991, Journal of immunology.

[25]  B. Walker,et al.  An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Rammensee,et al.  Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide , 1991, The Journal of experimental medicine.

[27]  S. Riddell,et al.  Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. , 1991, Reviews of infectious diseases.

[28]  Timothy E. Elliott,et al.  A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.

[29]  M. Keller,et al.  Evidence for idiotypic sharing between conventional and naturally activated B cells , 1991, European journal of immunology.

[30]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[31]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[32]  W. Britt,et al.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.

[33]  P. Cresswell,et al.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex , 1990, Nature.

[34]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[35]  T. Leanderson,et al.  Clonal Selection in B‐Cell Growth and Differentiation , 1987, Immunological reviews.

[36]  N. Shastri,et al.  The Choice of T‐Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site , 1987, Immunological Reviews.

[37]  K Kumagai,et al.  A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. , 1987, Journal of immunological methods.

[38]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[39]  B. Barrell,et al.  Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus , 1987, Journal of virology.

[40]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.

[41]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[42]  H. Orr,et al.  Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Riggs,et al.  Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Gibson,et al.  Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. , 1984, Birth defects original article series.

[45]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[46]  C. Barnstable,et al.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.

[47]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.